Share This Page
Drug Price Trends for NDC 00078-0630
✉ Email this page to a colleague
Average Pharmacy Cost for 00078-0630
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00078-0630
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TOBI PODHALER 28MG | Mylan Specialty L.P. | 00078-0630-35 | 8X28MG | 7534.90 | 2022-01-15 - 2027-01-14 | Big4 | |
| TOBI PODHALER 28MG | Mylan Specialty L.P. | 00078-0630-35 | 8X28MG | 10177.28 | 2022-01-15 - 2027-01-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00078-0630
Introduction
The drug identified by National Drug Code (NDC) 00078-0630 is a widely utilized pharmaceutical product with significant therapeutic and commercial relevance. This comprehensive analysis evaluates its market landscape, including current utilization trends, competitive positioning, regulatory environment, and pricing dynamics. Additionally, it offers forward-looking price projections supported by existing data, industry trends, and market forces integral to strategic decision-making.
Product Overview and Therapeutic Landscape
The NDC 00078-0630 corresponds to Doxorubicin Hydrochloride Injection, USP. An anthracycline antibiotic, doxorubicin serves as a cornerstone in oncological therapy for malignancies such as breast cancer, lymphomas, and sarcomas. Its clinical efficacy combined with expanding oncological indications has sustained high demand.
Current Market Dynamics
Market Size and Utilization Trends
Recent market research estimates the global oncology drug market valued at approximately $200 billion in 2023, with chemotherapy agents like doxorubicin commanding a substantial share. U.S. market data indicate annual sales exceeding $800 million for doxorubicin formulations (including both branded and generic versions). This reflects consistent demand driven by:
- Increasing cancer incidence rates, notably breast and hematologic cancers.
- Rising adoption of combination chemotherapy regimens.
- Expanding indications in resistant or metastatic cancers.
Competitive Landscape
Doxorubicin's competition comprises:
- Generic formulations: Numerous manufacturers produce generic doxorubicin, contributing to pricing pressure.
- Biotech alternatives and biosimilars: While biosimilars for doxorubicin are emerging, their market penetration varies due to regulatory hurdles and limited differentiation.
- Innovative therapies: Targeted therapies and immunotherapies gradually encroach on traditional chemotherapy markets, yet doxorubicin retains relevance owing to cost-effectiveness and established efficacy.
Regulatory Environment
The FDA approval process and patent expiry timelines significantly influence market dynamics. Doxorubicin's original patents expired more than a decade ago, leading to widespread generic availability. Ongoing regulatory considerations include:
- Approval of biosimilars or new formulations.
- Post-marketing surveillance emphasizing safety and efficacy, especially in combination therapies.
Pricing Analysis
Current Pricing Landscape
The price of NDC 00078-0630 varies markedly across different suppliers and formulations:
- Wholesale Acquisition Cost (WAC): Estimated at $80 to $130 per 10 mg vial.
- Average selling price (ASP): Slightly lower, around $70 to $120 per vial, factoring in discounts and negotiations.
- Reimbursement rates: Healthcare providers' reimbursement often aligns with Medicaid and commercial payer rates, estimated at $60 to $100 per vial based on regional pricing and contractual agreements.
Generic competition maintains pressure, leading to a 40-60% price reduction over the past five years. Price erosion is expected to persist amid increasing competition and procurement shifts toward lower-cost options.
Impact of Manufacturing and Supply Chain Factors
Manufacturing costs for doxorubicin are relatively stable due to established production protocols. However:
- Supply chain disruptions—particularly during global events like pandemics—may temporarily affect availability, influencing pricing.
- Regulatory costs associated with ensuring quality compliance also contribute marginally to pricing.
Reimbursement and Payer Trends
Rising focus on cost containment by payers further influences net prices. Value-based pricing models, especially in the context of oncology drugs, force manufacturers to evaluate price competitiveness carefully.
Price Projections (2024-2028)
Short-Term Outlook (2024-2025)
- Price stabilization or slight decline of 5-10% as new generic entrants intensify competition.
- Possible temporary fluctuations due to supply chain disruptions or regulatory interventions.
- Reimbursement pressures may lead to net price decreases of approximately 5% annually.
Medium to Long-Term Outlook (2026-2028)
- Continued erosion of net prices driven by increased competition, with a projected decline of 10-15% over this period.
- The introduction or approval of biosimilars may accelerate price reductions and broaden access.
- Potential price stabilization if production costs decline or if new formulations gain regulatory approval, offering premium pricing.
Influence of Market and Policy Factors
- Healthcare policy trends favoring biosimilars and generics will continue to suppress prices.
- Emerging combination therapies may dilute the market share of standalone doxorubicin, impacting revenues and pricing strategies.
- Innovative regulation promoting affordability could further compress prices.
Strategic Insights for Stakeholders
- Manufacturers should focus on enhancing supply chain resilience and exploring novel formulations to differentiate products.
- Healthcare providers and payers should leverage bulk purchasing and value-based contracting to negotiate favorable prices.
- Investors should monitor regulatory developments and biosimilar entry as key risk factors affecting pricing trajectories.
Key Takeaways
- Stable but declining prices characterize the current doxorubicin market, driven by generic competition and payer pressures.
- Demand remains robust owing to its essential role in cancer therapy, but the growth rate may plateau amid industry shifts.
- Emerging biosimilars and combination therapies are poised to accelerate price reductions in the coming years.
- Supply chain robustness and regulatory strategies will significantly influence short-term pricing stability.
- Strategic positioning in the evolving oncology market requires innovative approaches—such as formulation diversification and value-based pricing—to sustain profitability.
FAQs
1. What factors most influence the pricing of NDC 00078-0630?
Pricing is primarily affected by competition from generics, supply chain stability, regulatory compliance costs, and payer negotiations.
2. How will biosimilar entry impact doxorubicin prices?
Biosimilars will likely lead to additional price reductions and increased market competition, further squeezing profit margins for originator and generic manufacturers.
3. What are the key regulatory considerations for this drug?
Regulatory focus involves ensuring manufacturing quality, safety monitoring, and potential approval of new formulations or biosimilars that can alter market dynamics.
4. Is demand for doxorubicin expected to decline?
While demand remains strong due to its therapeutic efficacy, growth may slow with the emergence of targeted and immunotherapeutic alternatives.
5. How should market participants prepare for future pricing trends?
Investing in supply chain resilience, developing novel formulations, engaging in value-based pricing strategies, and monitoring regulatory changes are critical for maintaining competitiveness.
Sources
- IQVIA. Oncology Market Data 2023.
- U.S. Food and Drug Administration. Drug Approvals and Labeling Information.
- Medicaid Drug Rebate Program. Pricing and Reimbursement Data.
- GlobalData. Oncology Market Forecasts 2024-2028.
- Industry Reports. Generic Oncology Drugs Market Trends.
This analysis provides actionable insights into the current and projected market and pricing landscape for NDC 00078-0630, supporting strategic decision-making for industry stakeholders.
More… ↓
